Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.41 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.41 |
| ▸ | CHRM3 known ✓ | P20309 | 1/20 | 0.41 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 9/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.43 |
| ▸ | MLNR | O43193 | 1/20 | 0.41 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.41 |
| ▸ | PGR | P06401 | 1/20 | 0.41 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.41 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2199197 | 1.00 | CYP2D6 (0.43) | CYP2D6CYP3A4MLNRNR1I2ESR1 | |
| Hydrochloric Acid SCHEMBL585238 | 0.98 | CYP2D6 (0.43) | CYP2D6CYP3A4MLNRNR1I2ESR1 | |
| Hydrochloric Acid SCHEMBL585206 | 0.98 | CYP2D6 (0.43) | CYP2D6CYP3A4MLNRNR1I2ESR1 | |
| Hydrochloric Acid SCHEMBL2202701 | 0.98 | CYP2D6 (0.43) | CYP2D6CYP3A4MLNRNR1I2ESR1 | |
| Hydrochloric Acid SCHEMBL586083 | 0.98 | CYP2D6 (0.43) | CYP2D6CYP3A4MLNRNR1I2ESR1 | |
| Hydrochloric Acid SCHEMBL2197152 | 0.98 | CYP2D6 (0.43) | CYP2D6CYP3A4MLNRNR1I2ESR1 | |
| Hydrochloric Acid SCHEMBL585438 | 0.98 | CYP2D6 (0.43) | CYP2D6CYP3A4MLNRNR1I2ESR1 | |
| Hydrochloric Acid SCHEMBL585453 | 0.98 | CYP2D6 (0.43) | CYP2D6CYP3A4MLNRNR1I2ESR1 | |
| Hydrochloric Acid SCHEMBL585887 | 0.90 | CYP2D6 (0.39) | CYP2D6CYP3A4ALDH1A1LMNAKDM4E | |
| Hydrochloric Acid SCHEMBL585215 | 0.87 | CHRNA7 (0.42) | CYP2D6CYP3A4RARBALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1768666-B1 | NOVEL USES OF PORPHYRIN COMPOUNDS | DESTINY PHARMA LTD (GB) | 2012-02-15 | — | — | EP | disclosed |
| US-7977474-B2 | Uses of porphyrin compounds | DESTINY PHARMA LTD. (GB) | 2011-07-12 | — | — | US | disclosed |
| EP-1897883-A2 | Cationic porphyrin derivatives as antibacterial agents | Destiny Pharma Limited (GB) | 2008-03-12 | — | — | EP | disclosed |
| EP-1578750-B1 | CATIONIC PORPHYRIN DERIVATIVES AS ANTIBACTERIAL AGENTS | DESTINY PHARMA LTD (GB) | 2007-11-21 | — | — | EP | disclosed |
| US-20070167619-A1 | Novel uses of porphyrin compounds | DESTINY PHARMA LTD. (GB) | 2007-07-19 | — | — | US | disclosed |
| US-7244841-B2 | Porphyrin derivatives and their use in photodynamic therapy | DESTINY PHARMA LIMITED (GB) | 2007-07-17 | — | — | US | disclosed |
| US-20040143001-A1 | Novel compounds and uses thereof | DESTINY PHARMA LIMITED | 2004-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167619-A1 | Novel uses of porphyrin compounds | PPOX, ZFX, ZYX | CHRM2 2736/4885CHRM1 1754/4885CHRM3 3127/4885 |
| US-20040143001-A1 | Novel compounds and uses thereof | PPOX, CYP19A1, XDH | CHRM2 2709/4885CHRM1 2458/4885CHRM3 3318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.